This post is my second post on Imugene’s cancer therapy regime. You can see the first one on their cancer therapy here. As per the last post, I’m pasting the email here in its entirety.
Dear all,
Hello from Leslie Chong.
I am excited to provide you with an important update on our Phase 1b HER-Vaxx gastric cancer trial in patients expressing the HER2 target protein.
Today we announced that we met our study endpoints and positive top-line results.
The 14 patient study tested three dose levels of HER-Vaxx (10, 30 and 50 micrograms) in combination with current standard of care chemotherapy, cisplatin and fluorouracil or capecitabine. All dose levels showed an increased antibody response in patients.
No safety issues were reported and HER-Vaxx was found to be well tolerated.
The study Cohort Review Committee recommended a dose of 50 micrograms for the Phase 2 dose based on the safety and immunogenicity data.
Response rate is an exploratory endpoint in the Phase 1b study; of the 10 patients evaluable for tumour growth assessment during the study, 5 patients showed partial response (PR) and 4 patients showed stable disease (SD) for their best overall response.
I would like to sincerely thank the medical researchers and patients who participated in this study. Together your Imugene team are cautiously encouraged by meeting all the endponts of the study and data from the top-line results in a small sample size, in particular the five patients whose best response showed more than 30% decrease in their tumour size from baseline scans.
With these early results from the HER-Vaxx clinical study, Imugene’s B-cell active immunotherapy approach is showing positive signs which provides us with further confidence in our B-cell immunotherapy pipeline. This is a promising milestone for Imugene and the many medical professionals seeking treatments for patients with advanced gastric cancer who often have very few medical options.
We look forward to reporting further milestones, obtaining patient data and commencing the Phase 2 trial in early 2019.
Please click here to view the release.
Warmest,
Leslie.
After checking mu Imugene Shares after their latest release, I thought there would have been a big jump in the share price, but I was surprised to find that didn’t happen. Reckon it’s going to take a lot more than that to get folk interested in investing money in a speculative cancer therapy regime.
